Last reviewed · How we verify
poloxamer 188
poloxamer 188 is a Small molecule drug developed by Mast Therapeutics, Inc.. It is currently FDA-approved.
Poloxamer 188, marketed by Mast Therapeutics, Inc., holds a unique position in its therapeutic segment with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence, leveraging its mechanism to address critical patient needs. The primary risk is the lack of revenue data and key trial results, which may limit investor confidence and competitive positioning.
At a glance
| Generic name | poloxamer 188 |
|---|---|
| Sponsor | Mast Therapeutics, Inc. |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants (PHASE3)
- Comparison of the Postoperative Analgesic Effects of the Temperature-responsive Gel Mixed With Local Anesthetics Application and Ultrasound-guided Transversus Abdominis Plane Block in Patients Undergoing Laparoscopic Gastrectomy (NA)
- Molecular Residual Disease Interception in Locoregionally-Advanced High Risk HPV+ and HPV- HNSCC (PHASE2)
- Antibacterial Mouthwash for Pharyngeal Gonorrhea Prevention (PHASE2)
- Pocket-X Gel Non-surgical Periodontal Therapy (NA)
- Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults (PHASE3)
- A Phase I Trial of IMA970A Plus Montanide in Combination With Durvalumab (Anti-PD-L1) (PHASE1)
- Study to Evaluate the Safety & Immunogenicity of IMNN-101 Administered in Healthy Adults Previously Vaccinated Against SARS-CoV-2 (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- poloxamer 188 CI brief — competitive landscape report
- poloxamer 188 updates RSS · CI watch RSS
- Mast Therapeutics, Inc. portfolio CI
Frequently asked questions about poloxamer 188
What is poloxamer 188?
Who makes poloxamer 188?
What development phase is poloxamer 188 in?
Related
- Manufacturer: Mast Therapeutics, Inc. — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing